Active substances
Ciprofloxacin + Dexamethasone
- US FDA 6
- Health Canada 3
- NHS prices 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CIPRODEX | 0.3%;0.1% | suspension/drops · otic | SANDOZ | Prescription | 18 Jul 2003 |
| CIPROFLOXACIN AND DEXAMETHASONE | 0.3%;0.1% | suspension/drops · otic | DR REDDYS | Prescription | 10 Aug 2020 |
| CIPROFLOXACIN AND DEXAMETHASONE | 0.3%;0.1% | suspension/drops · otic | SUN PHARM | Prescription | 30 Aug 2022 |
| CIPROFLOXACIN AND DEXAMETHASONE | 0.3%;0.1% | suspension/drops · otic | SENTISS | Prescription | 9 Jun 2023 |
| CIPROFLOXACIN AND DEXAMETHASONE | 0.3%;0.1% | suspension/drops · otic | AMNEAL | Prescription | 22 Mar 2024 |
| CIPROFLOXACIN AND DEXAMETHASONE | 0.3%;0.1% | suspension/drops · otic | UPSHER SMITH LABS | Prescription | 6 Jan 2026 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CIPRODEX | 02252716 | 0.3 % / W/V; 0.1 % / W/V | SUSPENSION · OTIC | NOVARTIS PHARMACEUTICALS CANADA INC |
| SANDOZ CIPROFLOXACIN / DEXAMETHASONE | 02506882 | 0.3 % / W/V; 0.1 % / W/V | SUSPENSION · OTIC | SANDOZ CANADA INCORPORATED |
| TARO-CIPROFLOXACIN/DEXAMETHASONE | 02481901 | 0.3 % / W/V; 0.1 % / W/V | SUSPENSION · OTIC | TARO PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Ciprofloxacin 0.3% / Dexamethasone 0.1% ear drops | £6.12 | 5 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.